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Abstract
Epithelial-mesenchymal transition (EMT) is a crucial step for the acquisition of invasive properties of carcinoma cells during
tumor progression. Epidermal growth factor (EGF)-treatment of squamous cell carcinoma (SCC) cells provokes changes in
the expression of lineage markers, morphological changes, and a higher invasive and metastatic potential. Here we show
that chronic stimulation with EGF induces EMT in skin-derived SCC cell lines along with the down-regulation of the epithelial
marker E-cadherin, and of the putative tumor suppressor VILIP-1 (visinin-like protein 1). In esophageal squamous cell
carcinoma and non-small cell lung carcinoma the loss of VILIP-1 correlates with clinicopathological features related to
enhanced invasiveness. VILIP-1 has previously been shown to suppress tumor cell invasion via enhancing cAMP-signaling in
a murine SCC model. In mouse skin SCC cell lines the VILIP-1-negative tumor cells have low cAMP levels, whereas VILIP-1-
positive SCCs possess high cAMP levels, but low invasive properties. We show that in VILIP-1-negative SCCs, Snail1, a
transcriptional repressor involved in EMT, is up-regulated. Snail1 expression is reduced by ectopic VILIP-1-expression in
VILIP-1-negative SCC cells, and application of the general adenylyl cyclase inhibitor 29,39-dideoxyadenosine attenuated this
effect. Conversely, EGF-stimulation of VILIP-1-positive SCC cells leads to the down-regulation of VILIP-1 and the induction of
Snail1 expression. The induction of Snail is inhibited by elevated cAMP levels. The role of cAMP in EMT was further
highlighted by its suppressive effect on the EGF-induced enhancement of migration in VILIP-1-positive SCC cells. These
findings indicate that VILIP-1 is involved in EMT of SCC by regulating the transcription factor Snail1 in a cAMP-dependent
manner.
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Introduction
Cell motility is a prerequisite for tumor progression and for
invasive migration of carcinoma cells into surrounding tissue. In
order to acquire a motile phenotype carcinoma cells undergo a
dramatic morphological alteration, termed epithelial–mesenchy-
mal transition (EMT), wherein they lose their epithelial charac-
teristics and acquire the motility of mesenchymal cells [1]. In the
case of many carcinomas, EMT-inducing signals, such as HGF,
EGF, PDGF, and TGF-b, emanate from the tumor-associated
stroma and activate a series of EMT-inducing transcription
factors, including Snail, Slug, zinc finger E-box binding homeobox
1 (ZEB1), Twist, Goosecoid, and FOXC2. These transcription
factors pleiotropically orchestrate the complex EMT program [2].
The loss of cell–cell contacts mediated by E-cadherin, an epithelial
marker, is a typical hallmark of EMT [3]. The down-regulation of
E-cadherin is common in squamous cell carcinomas (SCC) and is
associated with an enhanced ability of invasion and/or metastasis
and with a poor prognosis [4–6], reflective of its critical role in
tumor progression. It is widely believed that the down-regulation
of E-cadherin occurs through the transcriptional repression
mediated by binding of transcriptional repressors, such as Snail1
(SNAI1) [7,8], to E-box sequences in the proximal E-cadherin
promoter [9]. The EMT program and the activation of Snail1
depends on a series of intracellular signaling networks and
feedback loops involving ERK, MAPK, PI3K, and Akt signaling
pathways [10]. In contrast, little is known about the involvement of
cyclic nucleotide-mediated signaling pathways in EMT. These
pathways are implicated in many biological processes that
cooperate in organ development and differentiation of epithelial
cells. The effects of cyclic adenosine monophosphate (cAMP) via
protein kinase A (PKA) on changes in cell motility and via
exchange protein activated by cAMP (EPAC) on cell migration
[11] and integrin-mediated cell adhesion [12] are particularly
important for tumor invasion. Intracellular cAMP concentrations
are regulated by adenyl cyclases (AC), which use ATP to produce
cAMP, and by phosphodiesterases (PDEs), which catalyze the
degradation of cAMP to AMP [13].
Visinin-like protein 1 (VILIP-1, gene name VSNL1), a member
of the family of neuronal calcium sensor proteins [14], modulates
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and has recently been identified as a putative tumor migration
suppressor gene [18,19]. In esophageal cancer the reduced
expression of VILIP-1 is correlated with invasive features, such
as the depth of tumor invasion and local lymph node metastasis
[20]. In aggressive non-small cell lung carinoma cell lines and
primary tumors the loss of VILIP-1 expression is associated with a
poor survival [21]. VILIP-1 is differentially expressed in
chemically-induced murine skin squamous carcinomas of different
degrees of aggressiveness. In an experimental model of murine
SCC cell lines derived from these tumors it was demonstrated that
the ectopic expression of VILIP-1 in two VILIP-1 non-expressing,
high grade SCC lines increased cAMP levels, leading to a
diminished MMP-9 and RhoA activity together with a significant
reduction in the invasive properties of the carcinoma cells [18].
VILIP-1 expression was further shown to decrease the expression
of fibronectin-specific integrin subunits a5 and av that contributed
to cell adhesion, cell migration, and invasiveness of highly invasive
SCC cell lines [19]. Recently, we demonstrated that the tumor
invasion suppressing effect of VILIP-1 in mouse skin SCCs
exclusively depends on cAMP levels, but not on cGMP levels, and
that both cAMP-effectors, PKA and EPAC, are involved in the
reduction of the migratory ability of SCC cells [22]. Here, we set
out to investigate, whether and how VILIP-1-enhanced cAMP-
signaling may be involved in EMT in SCC.
Materials and Methods
Material
FSK (adenylyl cyclase activator Forskolin), 8Br-cAMP, DDA
(29,59-dideoxyadenosine, general AC inhibitor) EGF and TGFb
for cell stimulation experiments were obtained from Sigma (St.
Louis, MO, USA), Tocris (Bristol, UK) and Calbiochem (San
Diego, CA, USA). Cell culture reagents were obtained from
Gibco-Invitrogen (San Diego, CA, USA). Unless otherwise
specified, all other reagents were purchased from Sigma and
Roth (Karlsruhe, Germany).
Antibodies
Rabbit polyclonal antibodies, raised against recombinant
VILIP-1 protein, were affinity-purified on corresponding glu-
tathion-S-transferase (GST)-tagged fusion proteins, immobilized
on N-hydroxysuccinimide ester coupled agarose colums (Bio-Rad,
Hercules, CA, USA) as previously described [23]. Polyclonal
rabbit anti E-cadherin (gp184) antibodies were kindly provided by
Otmar Huber and described previously [24]. Polyclonal rabbit
anti integrin a5 antibodies were purchased from Chemicon
(Temecula, CA, USA) and monoclonal antibodies against b-actin
(sc-81178) and HRP-labeled secondary antibodies were purchased
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Cells and culture method
Murine skin squamous cell carcinoma cell lines CC4A and
CC4B, CH72 and CH72T3 were described previously [17].
CC4A and CC4B were derived from the same tumor. When
injected s.c. into nude mice, CC4A gave rise to a high-grade SCC
or spindle cell carcinoma (or SCC IV), whereas CC4B gave rise to
a well-differentiated, less aggressive, and low-grade SCC (SCCII).
CH72 also gave rise to a low-grade SCC after s.c. inoculation, and
CH72T3 is a subcloned cell line obtained by in vivo passaging of
CH72 into nude mice, which resulted in a high-grade SCC. Cells
were grown in DMEM (GIBCO) plus FCS (10%), L-glutamine
(2 mM) and penicillin/streptomycin (100 mg/ml).
Growth factor treatment
CC4B and CH72 cells were plated in standard DMEM in 24-
well or 6-well dishes, respectively. 24 h after plating and 8 h prior
to treatment with EGF or TGFb medium was exchanged to low
FCS (1%) DMEM to basal the cells. Cells were treated for 72 h
with the indicated concentrations of growth factors and afterwards
lysed for Western blot or RT-PCR analysis. To compare
morphological changes cells were fixed and images were taken
with a Leica inverted microscope at a 2006 magnification. The
migratory capacity of the cells after growth factor treatment was
analyzed in in vitro wounding assays over 24 h. In indicated cases
agents increasing or decreasing cAMP concentrations were added
24 h before cell lysis or before wounding the cell monolayer.
Transfection
CC4A and CH72T3 were transfected with VILIP-1-GFP-
vector or empty-GFP-vector [26] whereas CC4B and CH72 were
transfected with VILIP-1-siRNA or scrambled siRNA using
Optimem and lipofectamin 2000 (Invitrogen) following the
manufacturer’s instructions. VILIP-1-siRNA (antiVILIP1_1: sense
r(AGC CGU UAG UCU GAA UUA A)dTdT, antisense r(UUA
AUU CAG ACU AAC GGC U)dAdA; antiVILIP1_2: sense
r(CAA AGA UGA CCA GAU UAC A)dTdT, antisense r(UGU
AAU CUG GUC AUC UUU G)dAdA; antiVILIP1_3: sense
r(GUG CGA CAU UCA GAA AUG A)dTdT, antisense r(UCA
UUU CUG AAU GUC GCA C)dAdA) was used as a cocktail of
three siRNA oligos (150 ng of each per transfection) directed
against the coding region of VILIP-1 and was purchased from
Qiagen (Hilden, Germany).
Western blot analysis
Cultured cells were homogenized in an appropriate volume of
homogenization buffer (25 mM Tris, 150 mM NaCl, pH 7.5,
containing the protease inhibitors benzamidine (1 mM), phenyl-
methylsulfonylfluoride (0.1 mM)). Nuclei and debris were removed
by centrifugation at 1.000 g for 5 min, protein concentrations
were measured using BCA assay (Pierce, Rockford, IL, USA) and
40 mg protein of each sample was applied to 5–20% gradient SDS-
PAGE. To analyze the expression level of VILIP-1, E-cadherin,
integrin a5 and b-actin separated proteins were blotted on a
PVDF membrane. The membrane was blocked with 5% milk
powder in TBST (25 mM Tris, 150 mM NaCl, pH 7.5, 1%
Tween 20) for 1 h at RT and afterwards incubated with the
primary antibodies at 4uC overnight as previously described. After
washing three times with TBST, secondary antibodies were
applied for one hour at RT. Unbound antibodies were removed
and the detected protein was visualized in a dark chamber using
Western Lightning reagents (PerkinElmer Life Sciences, Boston,
MA USA) and Hyperfilm (Amersham, UK).
RT-PCR
PCR primers were designed that selectively amplify cDNA
encoding Snail1, VILIP-1 or GAPDH and synthezised by
Invitrogen (Carlsbad, CA,USA) (Snail1: sense AGG ACG CGT
GTG TGG AGT, antisense GGAGAATGG CTT CTC ACC
AG; VILIP-1: sense ATG GGG AAR CAG AAT AGC AAA C,
antisense TCA TTT CTG MAT GTC KCA CTG CA; GAPDH:
sense ACC ACA GTC CAT GCC ATC AC, antisense TCC
ACC ACC CTG TTG CTG TA; K, M, R indicate mixed bases
used to obtain species-independent primers). RT-PCR experi-
ments were performed 3 times using total RNA from SCC-lines.
Total RNA was extracted using RNeasy Mini-Kit (Quiagen,
Hilden, Germany) and reverse transcribed using Oligo(dT)
VILIP-1 in Epithelial-Mesenchymal Transition
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Diego, CA, USA). PCR was performed using 0.2 mM of each
primer, PCR buffer, 0.2 mM dNTP-Mix, 2 mM MgCl2, and 1 U
taq polymerase (Invitrogen, San Diego, CA, USA) and DEPCH2O
in a 50 ml reaction mix. 35 cycles of amplification were performed
for each sample. For each primer pair the reaction was also carried
out in absence of reverse transcriptase to ensure that there is no
DNA contamination.
In vitro wound assay
Cells grown in standard medium (2610
5 cells/well) were plated
in 24-well plates. Cells were either grown in low FCS (1%)
medium for 8 h and then treated with 10 ng/ml EGF in low FCS
(1%) medium for 72 h before wounding or were transfected with
VILIP-1-siRNA or the corresponding control 72 h before
wounding and grown to confluence. Cells were placed in low
FCS (1%) medium in order to basal the cells prior to growth factor
treatment and to minimize cell proliferation. A wound was created
by scratching the cell monolayer using a sterile 200 ml pipette tip.
The wound was marked and 24 h after wounding cells were fixed
and pictures were taken at a 2006 magnification with a Leica
inverted microscope and at least eight representative fields for each
condition were analyzed. Cell migration was quantified by
counting the number of cells/field.
Statistical analysis
Statistical analysis was performed using unpaired, two-sided
Student’s t-test for samples of unequal variance (Welch test).
Values were accepted as significant when p was less than 0.05 (*),
less than 0.01 (**) or less than 0.001 (***). All error bars represent
standard deviations.
Results
Epithelial-mesenchymal transition (EMT) in squamous cell
carcinoma (SCC)
When we compared the morphology of cultures of the less
aggressive, VILIP-1-positive skin cancer cells (CC4B and CH72)
with the more aggressive, VILIP-1-negative skin cancer cells
(CC4A and CH72T3), obvious morphological differences were
noticed. Less aggressive, VILIP-1-positive skin cancer cells (CC4B
and CH72) were well organized, tightly packed and formed
clustered, cobblestone-like structures, typical of epithelial cells and
suggestive of strong cell–cell adhesion. In contrast, aggressive,
VILIP-1-negative skin cancer cells (CC4A and CH72T3) showed
the mesenchymal morphological phenotype, including cell shape
elongation and scattering of cells, which is suggestive of reduced
cell–cell adhesion and increased cell motility (Fig. 1A). Since cell-
cell adherens junctions of epithelial cells are formed by E-cadherin
molecules, we assessed the cellular expression levels of E-cadherin
in VILIP-1-negative and VILIP-1-positive SCCs. Immunoblotting
showed that the expression of E-cadherin was down-regulated in
VILIP-1-non-expressing cell lines CC4A and CH72T3, compared
to VILIP-1-expressing cell lines CC4B and CH72. In contrast the
integrin receptor subunit a5, mediating cell-matrix adhesion, was
up-regulated in VILIP-1-non-expressing cells (Fig. 1B). The loss of
the epithelial, cell type-specific morphology, the loss of E-cadherin
expression and the associated reduction of cell-cell adherens
junctions are hallmarks of EMT. These results suggest that
aggressive SCCs must have undergone EMT while losing VILIP-
1-expression.
Growth factor-induced EMT: changes in cell morphology
and expression of marker proteins in SCC
Growth factors, especially TGFb and EGF, have been shown to
induce EMT along with the down-regulation of various epithelial
markers, including E-cadherin, in SCC [25]. We thus examined
whether the stimulation of VILIP-1-positive CC4B and CH72
cells with different concentrations of TGFb or EGF promotes
EMT-like morphological changes and corresponding alterations in
expression levels of VILIP-1, E-cadherin and integrin a5. When
TGFb-treated CC4B and CH72 cells were compared to untreated
cells (control), they appeared rounded in cell shape (Fig. 2A,
second panel) and immunoblotting revealed increased integrin a5
expression levels and slightly reduced VILIP-1 expression levels
(Fig. 2B, lanes 2 and 3). In terms of E-cadherin protein levels, the
induced alterations were not consistent between the two cell lines.
Contrary to expectations, in CC4B cells E-cadherin protein levels
cells seemed increased following TGFb treatment (Fig. 2B lanes 2
and 3, upper panel) and correspondingly CC4B cells did not show
scattering (Fig. 2A, upper row, second panel). However, CH72 cell
responded in an inhomogeneous manner to TGFb treatment.
Stimulated CH72 monolayers exhibited areas of scattered cells
(Fig. 2A, lower row, second panel) and stimulation with 0.1 ng/ml
TGFb slightly reduced E-cadherin protein levels in 2 of 3 repeats,
whereas stimulation with 1 ng/ml TGFb slightly increased E-
cadherin expression (Fig. 2B, lower panel). In summary, TGFb
treatment had only moderate effects on VILIP-1 protein levels, did
not alter or even tend to increase E-cadherin protein levels and did
not lead to widespread cell scattering or cell shape elongation.
Hence, TGFb did not cause a shift from the VILIP-1-positive, less
aggressive phenotype to the VILIP-1-negative, aggressive pheno-
type of SCC. By comparison, EGF treatment at 10 ng/ml resulted
in a more obvious cell shape elongation and scattering of CC4B
and CH72 cells (Fig. 2A third panel). Immunoblotting showed that
EGF at 10 ng/ml caused down-regulation of E-cadherin in both
carcinoma lines, which was consistent with the observed EGF-
induced cell morphological changes. Interestingly, the expression
of VILIP-1 was also clearly down-regulated in both cell lines in
response to stimulation with 10 ng/ml EGF. Stimulation with
1 ng/ml EGF did produce a less pronounced down-regulation of
E-cadherin and VILIP-1. Integrin a5 was up-regulated with
increasing EGF concentrations in both cell lines (Fig. 2B, lanes 4
and 5). Collectively, the stimulation at the higher EGF
concentration (10 ng/ml) induced clear EMT-like changes, and
resulted in a shift in the morphology and the protein expression of
VILIP-1-positive, less aggressive SCCs towards the phenotype of
VILIP-1-negative, more aggressive SCCs shown in Fig. 1.
Effect of the modulation of VILIP-1-expression on integrin
a5 and E-cadherin expression
In a previous study it has been shown that the knock down of
VILIP-1-expression caused an increase in the expression level of
integrin a5 and av in skin SCC [19]. Similarly, we found an
increased expression of integrin a5, while VILIP-1 expression was
down-regulated following EGF-stimulation. To determine whether
the loss of VILIP-1 also affected the expression of E-cadherin, we
transfected VILIP-1-negative SCCs with GFP-VILIP-1 or empty
GFP-vector as control, and VILIP-1-positive SCCs with VILIP-1-
specific siRNA or scrambled siRNA as control for 72 h
respectively and assessed protein levels of E-cadherin (Fig. 3).
Immunoblotting confirmed that integrin a5 expression is inversely
regulated by VILIP-1 (down-regulation in CC4A by 42%, in
CC72T3 by 44%; up-regulation in CC4B by 37%, in CH72 by
55%). In contrast, no effect of either VILIP-1 overexpression in
VILIP-1 in Epithelial-Mesenchymal Transition
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down in VILIP-1-positive SCCs CC4B and CH72 on E-cadherin
expression was observed, indicating that E-cadherin and VILIP-1
are independently down-regulated by EGF during EMT.
Expression levels of Snail1 mRNA in VILIP-1-positive and
VILIP-1-negative SCC and effect of EGF
Snail1 (SNAI1), a member of the slug/snail family of
transcriptional repressors [8], is one of the several transcriptional
factors that can suppress E-cadherin gene expression in squamous
cell carcinoma and is a potent inducer of EMT [26,27].
Accumulating evidence indicates that the EGFR family and its
downstream signaling pathways, the PI3K–Akt- and MEK–ERK
pathway, regulate the expression of Snail1 [28–31], suggesting
Snail1 as a candidate repressor for the down-regulation of VILIP-
1 and E-cadherin expression in response to stimulation with EGF
in mouse skin SCC. To verify this hypothesis we first determined
the expression of Snail1 in the aggressive and less aggressive SCC
cell lines. RT-PCR analysis showed that Snail1 mRNA is solely
detectable in VILIP-1-negative aggressive SCC cell lines (Fig. 4A).
However, following EGF stimulation and subsequent EMT-
induction, Snail1 was up-regulated in VILIP-1-positive SCC cell
lines (Fig. 4B). Interestingly, the induction of Snail1 expression in
response to EGF was diminished in the presence of elevated cAMP
following forskolin (FSK) stimulation (Fig. 4B), indicating a novel
role of cAMP-signaling in EMT. Quantification of the RT-PCR
showed that the EGF-induced increase of Snail1 mRNA was
statistically significant compared to control (Fig. 4C; CC4B+EGF:
p=0.039, CH72+EGF: p=0.029). Co-treatment with EGF and
forskolin significantly attenuated the EGF-induced increase of
Snail1 mRNA (Fig. 4C; CC4B+EGF+FSK: p=0.04,
CH72+EGF+FSK: p=0.047).
The effect of the modulation of VILIP-1-expression on
Snail1-expression depends on cAMP-signaling
Since the expression of VILIP-1 increases intracellular levels of
cAMP in skin SCC [18], we analyzed the effect of VILIP-1 and
cAMP-signaling on Snail1 mRNA levels. Following transfection of
VILIP-1-negative SCCs with GFP-VILIP-1 or empty GFP-vector
as control, and VILIP-1-positive SCCs with VILIP-1-specific
siRNA or scrambled siRNA as control for 72 h, we found that
knock down of VILIP-1-expression did not affect Snail1 mRNA
expression. In contrast, ectopic expression of VILIP-1 in the
aggressive, VILIP-1-negative cell lines CC4A and CH72T3
reduced Snail1 mRNA levels (Fig. 5A). The reduction of Snail1
mRNA was statistically significant (Fig. 5B; CC4A: p=0.035,
Figure 1. EMT-related differences in the characteristics of VILIP-1-positive and VILIP-1-negative SCC. A. Differences in morphology and
in the formation of cell-cell contacts between VILIP-1-negative, aggressive CC4A and CH72T3 cells and the VILIP-1-positive, less aggressive CC4B and
CH72 cells. B. Western Blot analysis showing the reciprocal expression levels of the adhesion molecules E-cadherin and integrin a5 in the VILIP-1-
negative and -positive cell lines. As control for protein loading the b-actin levels were examined.
doi:10.1371/journal.pone.0033116.g001
Figure 2. Effects of growth factor treatment in VILIP-1-positive, less aggressive SCC. A. Changes in cell shape and cell-cell adhesion
following treatment of CC4B and CH72 with 1 ng/ml TGFb or 10 ng/ml EGF. B. Western Blot analysis showing the changes in the expression level of
integrin a5, E-cadherin and VILIP-1 following treatment with TGFb (lanes 2 and 3, 0.1 and 1 ng/ml) or EGF (lanes 4 and 5, 1 and 10 ng/ml). As control
for protein loading the b-actin levels were examined. Representative pictures out of three independent experiments are shown.
doi:10.1371/journal.pone.0033116.g002
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general adenylyl cyclase inhibitor DDA for 24 h before lysis
(Fig. 5A, 5B lanes 2 and 4 versus 3 and 6, respectively),
demonstrating that cAMP-signaling plays an important role for
the VILIP-1 effect on Snail1 expression.
Involvement of cAMP-signaling in the VILIP-1-siRNA- or
EGF-induced migration of SCC cells
To demonstrate the involvement of cAMP-signaling in the effect
of EMT-induction and of VILIP-1-expression on the migratory
capability of skin tumor cells, we performed in vitro wound closure
assays. We either knocked down VILIP-1-expression by siRNA or
applied EGF-stimulation leading to reduced VILIP-1-expression
(Fig. 6). Both the knock down of VILIP-1-expression by siRNA
and EGF treatment resulted in a significantly increased migratory
capability (Fig. 6B), documented by a higher number of migrating
cells in the wound area after 24 h (Fig. 6A). In CC4B cells VILIP-
1-specific siRNA enhanced the cell migration by 46% (p,0.001)
and EGF by 59% (p,0.001). In CH72 cells following siRNA
treatment 72% more (p,0.001) and following EGF treatment
60% more (p,0.001) migrating cells were observed. We have
previously shown that VILIP-1-negative SCCs show greater
migratory capability than their VILIP-1-positive counterparts,
and that this effect depends on decreased cAMP levels [18]. The
application of 8Br-cAMP 24 h before wounding of siRNA or EGF
treated cells prevented the enhancement of the migratory
capability and significantly reduced the number of cells in the
wound area (Fig. 6, A, B and C: p,0.001 in all conditions).
Following the additional 8Br-cAMP application, the number of
migrating cells was significantly lower than in control conditions
(Fig. 6; B: CC4B: p=0.009, CH72: p=0.002; C: CC4B p=0.037,
CH72 p=0.039), confirming that increased motility induced by
the loss of VILIP-1 or by EGF treatment is suppressed by cAMP-
signaling. These results point towards a role of the putative tumor
migration suppressor VILIP-1 and the associated cAMP pathway
for EMT in SCC.
Discussion
In this study, we examined the role of the putative tumor
invasion suppressor VILIP-1 and cAMP-signaling during EMT in
mouse skin tumor cell lines of different aggressiveness. When
aggressive, VILIP-1-negative SCCs were compared to less
aggressive VILIP-1-positive SCCs, distinct differences in mor-
phology were observed. These differences resemble the change in
cellular morphology during the transition of the epithelial to
mesenchymal phenotype. This assumption was further supported
by the results of the Western blot analysis, showing the loss of the
EMT-marker E-cadherin in VILIP-1-negative CC4A and
Figure 3. Effect of modulation of VILIP-1 levels on the
expression of EMT markers. Western Blot analysis showing
decreased expression of integrin a5 and unchanged E-cadherin
expression following ectopic expression of VILIP-1 (+GFP-VILIP-1:
47 kDa) in VILIP-1-negative SCCs, CC4A and CH72T3. Increased
expression of integrin a5 and unchanged E-cadherin expression is
observed following siRNA knock down of VILIP-1 in VILIP-1-positive
SCCs, CC4B and CH72, in comparison to the corresponding control-
treated SCC (endogenous VILIP-1: 22 kDa, compare lanes 3 and 4, and
lanes 7 and 8). As control for protein loading the b-actin levels were
examined.
doi:10.1371/journal.pone.0033116.g003
Figure 4. Expression levels of Snail1 mRNA in VILIP-1-positive
and VILIP-1-negative SCC and effect of EGF. A. RT-PCR analysis
showing the expression of Snail1 in VILIP-1-negative, aggressive CC4A
and CH72T3 cells using GAPDH mRNA expression as internal control. B.
Effect of EGF stimulation (lanes 2, 3 and 5, 6) and of additional forskolin
treatment (lanes 3 and 6) on the expression of Snail1 mRNA in VILIP-1-
positive, less aggressive CC4B and CH72 cells. For comparison the
expression of VILIP-1 mRNA and GAPDH mRNA is shown. Representa-
tive pictures of three independent experiments are shown. C.
Densitometry of RT-PCR analysis in B, lanes 1 to 6. Intensity of Snail1
bands was normalized to the intensity of GAPDH control PCR bands
(CC4B+EGF: p=0.039, CH72+EGF p=0.029, CC4B+EGF+FSK: p=0.04,
CH72+EGF+FSK: p=0.047). Bars represent the mean of three experi-
ments. Error bars indicate standard deviations. Asterisks indicate the
level of significance.
doi:10.1371/journal.pone.0033116.g004
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activity of two further EMT markers, RhoA and MMP9, in the
aggressive, VILIP-1 negative SCCs [18]. The spindle-like
morphology, the loss of the epithelial marker gene E-cadherin
together with the previously shown up-regulation in the activity of
RhoA, MMP9 and of the protein level of integrin a5, as well as the
enhanced migratory capability, indicate that VILIP-1-negative,
aggressive SCCs underwent EMT, and that down-regulation of
VILIP-1 might be related to EMT. To reproduce this process
experimentally, we stimulated VILIP-1-positive CC4B and CH72
cells with EMT-inducing growth factors TGFb and EGF. We
found that stimulation with EGF induces SCC cells to undergo a
transition from the epithelial to the spindle-like mesenchymal
morphology. This was accompanied by the loss of E-cadherin and
subsequent loss of cell-cell-contacts. Similar results have been
obtained for several other carcinoma cells by authors of previous
Figure 5. The effect of modulation of VILIP-1-expression and cAMP-signaling on Snail1 mRNA levels. A. RT-PCR analysis showing the
suppression of Snail1 mRNA by ectopic expression of VILIP-1 in VILIP-1-negative, aggressive CC4A and CH72T3 cells (lanes 2, 3 and 5, 6) and the
blocking of this effect by application of DDA (500 mM) (lanes 3, 6). siRNA knock down of VILIP-1 in VILIP-1-positive less aggressive CC4B and CH72
cells caused no alteration of the expression level of Snail1 (lanes 8, 10). B. Densitometry of RT-PCR analysis in A, lanes 1 to 6. Intensity of Snail1 bands
was normalized to the intensity of GAPDH control PCR bands (CC4A+VILIP-1: p=0.035, CH72T3+VILIP-1 p=0.037). Bars represent the mean of three
experiments. Error bars indicate standard deviations. Asterisks indicate the level of significance.
doi:10.1371/journal.pone.0033116.g005
Figure 6. Involvement of cAMP-signaling in VILIP-1-siRNA- or EGF-induced migration of SCC cells. Confluent monolayers of VILIP-1-
positive cells, CC4B and CH72, were wounded and the migratory capacity of the cells was measured within 24 hrs by counting the number of cells
per field in at least 8 fields from three different experiments. A. Representative wounds in monolayers of EGF- or siRNA-treated CC4B cells are shown
in comparison to untreated controls and to cells that were additionally treated with 8Br-cAMP (500 mM) 24 h before wounding. B. Quantification of
the migration-inducing effect of siRNA knock down of VILIP-1 with or without application of 8Br-cAMP in CC4B and CH72 cells (p,0.001 in all
conditions). C. Quantification of the migration-inducing effect of EGF-treatment with and without application of 8Br-cAMP (p,0.001 in all
conditions). Data represent mean values from at least three independent experiments and error bars indicate standard deviations. Asterisks indicate
the level of significance.
doi:10.1371/journal.pone.0033116.g006
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regulation of integrin a5, and most importantly to the down-
regulation of VILIP-1 in CC4B and CH72 cells. This affirms the
hypothesis that VILIP-1 is lost during EMT. EGF treatment of
CC4B and CH72 cells induced an EMT-like phenomenon and
caused VILIP-1-positive SCC cells to mimick the characteristics of
VILIP-1-negative SCC cells, including the gain of increased
migratory capability. In the literature TGFb was also shown to
induce EMT [34,35]. However, in CC4B and CH72 cells TGFb
caused rounding of cells, but not cell shape elongation, and only
slightly reduced E-cadherin in CH72 cells or even increased it in
CC4B cells. Such increased E-cadherin levels following TGFb
treatment have also been observed in human trophoblasts [36].
Another study revealed, that only 2 of 20 mouse cell lines treated
with TGFb responded with the induction of EMT [37]. In
keratinocytes it has been shown, that the induction of EMT by
TGFb depends on a hyperactive Ras-MAPK-pathway and that
without this prerequisite only reversible morphological alterations
are induced [38]. However, the loss of growth control induced by
TGFb that occurs at a late stage of mouse skin carcinogenesis is
independent of ras gene activation [36]. These findings might
explain the small effect of TGFb observed in this study. VILIP-1-
expression was not or only marginally affected by TGFb
treatment. Thus, EGF, rather than TGFb is a key factor in
malignant progression of squamous cell carcinoma lines.
The observed down-regulation of E-cadherin and VILIP-1-
expression during EGF-induced EMT might be caused either by a
parallel transcriptional repression of both genes or by a serial
mechanism, where reduced levels of VILIP-1/cAMP might
contribute in a second step to the down-regulation of E-cadherin.
We have previously shown that reduced VILIP-1/cAMP levels
contribute to the up-regulation of integrin a5 in mouse skin SCC
[19]. Therefore, we analyzed the expression of Snail1, as a potent
inducer of EMT and a transcriptional repressor of E-cadherin.
Snail1 was detectable in untreated aggressive, VILIP-1- and E-
cadherin-negative SCC cells and was inducible by EGF treatment
in less aggressive, VILIP-1-positive cells. These results suggest the
possible involvement of Snail1 in the repression of E-cadherin and
VILIP-1-expression during EMT of mouse skin SCC. The inverse
correlation of Snail1 and E-cadherin expression, together with the
up-regulation of Snail1 during EGF-induced EMT are in line with
findings from other studies investigating the characteristics of
invasive SCC [29,39,40]. It is widely believed that downstream
pathways of the EGFR, particularly the PI3K-Akt and MAPK
pathway, are involved in the initiation of Snail1 expression
through the regulation of NF-kB and AP-1, which act as
transcriptional activators of the Snail1 gene [8,40,41]. It is
noteworthy that in our study the enhancement of cAMP levels
by application of forskolin in EGF treated cells repressed EGF-
induced expression of Snail1, implicating cAMP-signaling in the
regulation of Snail1. Ectopic expression of VILIP-1 in aggressive,
VILIP-1-negative SCCs, which leads to increased cAMP levels
[18], likewise decreased the expression level of Snail1. This effect
could be blocked by the application of the general adenylyl cyclase
inhibitor DDA. To our knowledge this is the first study showing
that VILIP-1-dependent cAMP-signaling interferes with the
expression of Snail1 and might thereby prevent the progression
of EMT during tumor progression. Accumulating evidence
indicates that enhanced cAMP-signaling counteracts the malig-
nant progression of cancer cells [42,43]. A few studies also report
that cAMP-elevating agents block EMT [44–46]. In melanoma
cells cAMP regulates the NF-kB-mediated expression of EMT-
associated genes [44]. Among these genes were SIP1 and slug, two
other repressors of E-cadherin expression. In the alveolar epithelial
cell line A549 increased cAMP levels resulting from the inhibition
of cAMP-PDE4 block TGFb-induced EMT in a MAPK-signaling
dependent manner [46]. The two latter studies also describe a
cAMP-mediated regulation of E-cadherin expression, whereas in
other studies analyzing E-cadherin-mediated cell-cell-contacts and
migration of cancer cells no cAMP-dependent effect on E-
cadherin expression could be detected [11,47]. Although we
found a significant effect of VILIP-1 and cAMP-signaling on the
expression level of the E-cadherin repressor Snail1, we could not
detect any effect, neither of the knock down of VILIP-1 in the less
aggressive SCCs, nor of the over-expression of VILIP-1 in the
aggressive SCCs, on the expression of E-cadherin. Thus, we
conclude that VILIP-1 is not necessary for basal expression of E-
cadherin. Ectopic expression of VILIP-1 and subsequently
increased cAMP levels seem not to be sufficient to abolish an
established inactivation of the E-cadherin gene. Therefore, E-
cadherin and VILIP-1 are rather subject to a parallel transcrip-
tional repression during EGF-induced EMT in mouse skin SCC.
E-cadherin silencing involves a high degree of complexicity with
the cooperation of epigenetic mechanisms and different repressors
acting at different stages of the malignant progression [8]. Against
this background it has to be considered that the Snail1-reducing
effect of VILIP-1-cAMP might have an impact on the initial
down-regulation of E-cadherin expression during the first steps of
tumor progression, whereas in advanced stages the contribution of
additional factors is necessary to reconstitute the E-cadherin
expression. However, it is very likely that VILIP-1 and cAMP-
signaling regulates other Snail1 repressor target genes during
EMT. To understand this interesting phenomenon further studies
are required to decipher the precise mechanism of the VILIP-1-
cAMP-dependent Snail-1 regulation and its impact on gene
repression. For instance, the reduction of integrin a5b1 signaling
by VILIP-1/cAMP might be involved, since integrin a5b1 was
shown to act in concert with the EGFR and via ILK-Akt-NF-kB
signaling, which constitute two ways to influence the expression
level of Snail1 [8,41,48]. Another way to interfere with the
induction of the EMT program and Snail1 expression is the direct
crosstalk of cAMP-signaling with the signaling cascades down-
stream of the EGFR, such as interfering with the MAPK cascade
on the level of Raf or with PI3K pathways on the level of GSK3b
and NF-kB activity [44,49,50].
Further evidence for the EMT-suppressing role of VILIP-1-
cAMP-signaling comes from the in vitro wound closure assays. The
increase in the migratory capability of less aggressive, VILIP-1-
positive SCCs caused by either siRNA knock down of VILIP-1 or
EGF-treatment was eliminated by the application of 8Br-cAMP.
Other studies analyzing the effects of EGF on cell migration,
consistently describe an increase in the migratory capability
following EGF treatment [31,42]. As mentioned above the role of
cAMP in tumor progression is controversial. For example,
dibutyryl cAMP has been shown to slightly enhance collagen-
mediated keratinocyte migration [51]. In contrast, it has also been
shown that cAMP inhibits growth factor-mediated matrix
metalloproteinase 9 induction and keratinocyte migration [42].
We have reported in a previous study that in mouse skin SCC
enhanced cAMP-signaling reduced their migratory capability [22].
Accordingly, the results of the present study showed that the
migration-diminishing effect of cAMP-signaling counteracts the
migration-inducing effect of EGF, suppressing a further hallmark
of malignant tumors cells, which have undergone EMT.
In summary, the present study shows the role of the putative
tumor migration suppressor VILIP-1 in counteracting the
induction of EGF-induced EMT. Our finding that VILIP-1
suppresses the expression of the EMT-related transcriptional
VILIP-1 in Epithelial-Mesenchymal Transition
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33116repressor Snail1, and might thereby interfere with the induction of
EMT in a cAMP-dependent manner, suggests a novel mechanism
for the anti-invasive activity of VILIP-1-cAMP-signaling. There-
fore, further investigation of the signaling networks involved in the
VILIP-1-cAMP-mediated regulation of Snail1 and its targets in
malignant tumors may help to identify novel anti-cancer strategies.
Author Contributions
Conceived and designed the experiments: KS AJK KHB. Performed the
experiments: KS. Analyzed the data: KS KHB. Contributed reagents/
materials/analysis tools: AJK. Wrote the paper: KS KHB.
References
1. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131–142. nrm1835
[pii];10.1038/nrm1835 [doi].
2. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition.
J Clin Invest 119: 1420–1428. 39104 [pii];10.1172/JCI39104 [doi].
3. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and
Ig-CAMs in cancer. Nat Rev Cancer 4: 118–132. 10.1038/nrc1276 [doi].
4. Tian Z, Guo W, Zhang WG (2002) [The expression of E-cadherin in oral cancer
with different biological behavior]. Shanghai Kou Qiang Yi Xue 11: 350–352.
1209 [pii].
5. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, et al. (2004) Altered E-
cadherin and epidermal growth factor receptor expressions are associated with
patient survival in lung cancer: a study utilizing high-density tissue microarray
and immunohistochemistry. Mod Pathol 17: 430–439. 10.1038/mod-
pathol.3800041 [doi];3800041 [pii].
6. Dursun P, Yuce K, Usubutun A, Ayhan A (2007) Loss of epithelium cadherin
expression is associated with reduced overall survival and disease-free survival in
early-stage squamous cell cervical carcinoma. Int J Gynecol Cancer 17:
843–850. IJG876 [pii];10.1111/j.1525-1438.2007.00876.x [doi].
7. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000)
The transcription factor snail controls epithelial-mesenchymal transitions by
repressing E-cadherin expression. Nat Cell Biol 2: 76–83. 10.1038/35000025
[doi].
8. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour
progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:
415–428. nrc2131 [pii];10.1038/nrc2131 [doi].
9. Hemavathy K, Ashraf SI, Ip YT (2000) Snail/slug family of repressors: slowly
going into the fast lane of development and cancer. Gene 257: 1–12. S0378-
1119(00)00371-1 [pii].
10. Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, et al. (2010) Functional roles
of multiple feedback loops in extracellular signal-regulated kinase and Wnt
signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res
70: 6715–6724. 0008-5472.CAN-10-1377 [pii];10.1158/0008-5472.CAN-10-
1377 [doi].
11. Grandoch M, Rose A, ter Braak M, Jendrossek V, Rubben H, et al. (2009) Epac
inhibits migration and proliferation of human prostate carcinoma cells.
Br J Cancer 101: 2038–2042. 6605439 [pii];10.1038/sj.bjc.6605439 [doi].
12. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG (2006) Cell
physiology of cAMP sensor Epac. J Physiol 577: 5–15. jphysiol.2006.119644
[pii];10.1113/jphysiol.2006.119644 [doi].
13. Houslay MD, Adams DR (2010) Putting the lid on phosphodiesterase 4. Nat
Biotechnol 28: 38–40. nbt0110-38 [pii];10.1038/nbt0110-38 [doi].
14. Braunewell KH, Klein-Szanto AJ (2009) Visinin-like proteins (VSNLs):
interaction partners and emerging functions in signal transduction of a subfamily
of neuronal Ca2+ -sensor proteins. Cell Tissue Res 335: 301–316. 10.1007/
s00441-008-0716-3 [doi].
15. Brackmann M, Schuchmann S, Anand R, Braunewell KH (2005) Neuronal
Ca2+ sensor protein VILIP-1 affects cGMP signalling of guanylyl cyclase B by
regulating clathrin-dependent receptor recycling in hippocampal neurons. J Cell
Sci 118: 2495–2505. 118/11/2495 [pii];10.1242/jcs.02376 [doi].
16. Braunewell KH, Gundelfinger ED (1997) Low level expression of calcium-sensor
protein VILIP induces cAMP-dependent differentiation in rat C6 glioma cells.
Neurosci Lett 234: 139–142.
17. Lin L, Braunewell KH, Gundelfinger ED, Anand R (2002) Functional analysis
of calcium-binding EF-hand motifs of visinin-like protein-1. Biochem Biophys
Res Commun 296: 827–832. S0006291X02009439 [pii].
18. Mahloogi H, Gonzalez-Guerrico AM, Lopez De CR, Bassi DE, Goodrow T, et
al. (2003) Overexpression of the calcium sensor visinin-like protein-1 leads to a
cAMP-mediated decrease of in vivo and in vitro growth and invasiveness of
squamous cell carcinoma cells. Cancer Res 63: 4997–5004.
19. Gonzalez Guerrico AM, Jaffer ZM, Page RE, Braunewell KH, Chernoff J, et al.
(2005) Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration
in squamous carcinoma cells. Oncogene 24: 2307–2316. 1208476 [pii];10.1038/
sj.onc.1208476 [doi].
20. Wickborn C, Klein-Szanto AJ, Schlag PM, Braunewell KH (2006) Correlation
of visinin-like-protein-1 expression with clinicopathological features in squamous
cell carcinoma of the esophagus. Mol Carcinog 45: 572–581. 10.1002/mc.20201
[doi].
21. Fu J, Fong K, Bellacosa A, Ross E, Apostolou S, et al. (2008) VILIP-1
downregulation in non-small cell lung carcinomas: mechanisms and prediction
of survival. PLoS ONE 3: e1698. 10.1371/journal.pone.0001698 [doi].
22. Schonrath K, Pan W, Klein-Szanto AJ, Braunewell KH (2010) Involvement of
VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP
signaling in in vitro cell migration of murine skin squamous cell carcinoma. Mol
Carcinog10.1002/mc.20707 [doi].
23. Braunewell KH, Spilker C, Behnisch T, Gundelfinger ED (1997) The neuronal
calcium-sensor protein VILIP modulates cyclic AMP accumulation in stably
transfected C6 glioma cells: amino-terminal myristoylation determines func-
tional activity. J Neurochem 68: 2129–2139.
24. Huber O, Kemler R, Langosch D (1999) Mutations affecting transmembrane
segment interactions impair adhesiveness of E-cadherin. J Cell Sci 112(Pt 23):
4415–4423.
25. de Crane B, van Roy F, Berx G (2005) Unraveling signalling cascades for the
Snail family of transcription factors. Cell Signal 17: 535–547. S0898-
6568(04)00221-9 [pii];10.1016/j.cellsig.2004.10.011 [doi].
26. Hoot KE, Lighthall J, Han G, Lu SL, Li A, et al. (2008) Keratinocyte-specific
Smad2 ablation results in increased epithelial-mesenchymal transition during
skin cancer formation and progression. J Clin Invest 118: 2722–2732. 10.1172/
JCI33713 [doi].
27. Higashikawa K, Yoneda S, Tobiume K, Saitoh M, Taki M, et al. (2009)
DeltaNp63alpha-dependent expression of Id-3 distinctively suppresses the
invasiveness of human squamous cell carcinoma. Int J Cancer 124:
2837–2844. 10.1002/ijc.24280 [doi].
28. Hudson LG, Choi C, Newkirk KM, Parkhani J, Cooper KL, et al. (2007)
Ultraviolet radiation stimulates expression of Snail family transcription factors in
keratinocytes. Mol Carcinog 46: 257–268. 10.1002/mc.20257 [doi].
29. Lee MY, Chou CY, Tang MJ, Shen MR (2008) Epithelial-mesenchymal
transition in cervical cancer: correlation with tumor progression, epidermal
growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res
14: 4743–4750. 14/15/4743 [pii];10.1158/1078-0432.CCR-08-0234 [doi].
30. Qiao M, Sheng S, Pardee AB (2008) Metastasis and AKT activation. Cell Cycle
7: 2991–2996. 6784 [pii].
31. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, et al. (2006)
Molecular pathways regulating EGF-induced epithelio-mesenchymal transition
in human ovarian surface epithelium. Am J Physiol Cell Physiol 290:
C1532–C1542. 00478.2005 [pii];10.1152/ajpcell.00478.2005 [doi].
32. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, et al. (2007) Epidermal growth factor
receptor cooperates with signal transducer and activator of transcription 3 to
induce epithelial-mesenchymal transition in cancer cells via up-regulation of
TWIST gene expression. Cancer Res 67: 9066–9076. 67/19/9066
[pii];10.1158/0008-5472.CAN-07-0575 [doi].
33. Lu Z, Ghosh S, Wang Z, Hunter T (2003) Downregulation of caveolin-1
function by EGF leads to the loss of E-cadherin, increased transcriptional
activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4:
499–515. S1535610803003040 [pii].
34. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, et al. (2001)
Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal
transdifferentiation of pancreatic cancer cells requiring extracellular signal-
regulated kinase 2 activation. Cancer Res 61: 4222–4228.
35. Fujimoto K, Sheng H, Shao J, Beauchamp RD (2001) Transforming growth
factor-beta1 promotes invasiveness after cellular transformation with activated
Ras in intestinal epithelial cells. Exp Cell Res 266: 239–249. 10.1006/
excr.2000.5229 [doi];S0014-4827(00)95229-7 [pii].
36. Karmakar S, Das C (2004) Modulation of ezrin and E-cadherin expression by
IL-1beta and TGF-beta1 in human trophoblasts. J Reprod Immunol 64: 9–29.
S0165-0378(04)00096-8 [pii];10.1016/j.jri.2004.04.005 [doi].
37. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, et al. (2004) Induction
by transforming growth factor-beta1 of epithelial to mesenchymal transition is a
rare event in vitro. Breast Cancer Res 6: R215–R231. 10.1186/bcr778
[doi];bcr778 [pii].
38. Santibanez JF, Olivares D, Guerrero J, Martinez J (2003) Cyclic AMP inhibits
TGFbeta1-induced cell-scattering and invasiveness in murine-transformed
keratinocytes. Int J Cancer 107: 715–720. 10.1002/ijc.11457 [doi].
39. Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, et al. (2001) Reverse
correlation of E-cadherin and snail expression in oral squamous cell carcinoma
cells in vitro. Oral Oncol 37: 65–71. S1368-8375(00)00059-2 [pii].
40. Gan Y, Shi C, Inge L, Hibner M, Balducci J, et al. (2010) Differential roles of
ERK and Akt pathways in regulation of EGFR-mediated signaling and motility
in prostate cancer cells. Oncogene 29: 4947–4958. onc2010240 [pii];10.1038/
onc.2010.240 [doi].
41. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM (2005)
Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription:
implications for the epithelial-mesenchymal transition. J Cell Biol 168: 29–33.
jcb.200409067 [pii];10.1083/jcb.200409067 [doi].
42. McCawley LJ, Li S, Benavidez M, Halbleib J, Wattenberg EV, et al. (2000)
Elevation of intracellular cAMP inhibits growth factor-mediated matrix
VILIP-1 in Epithelial-Mesenchymal Transition
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33116metalloproteinase-9 induction and keratinocyte migration. Mol Pharmacol 58:
145–151.
43. Mukai M, Nakamura H, Tatsuta M, Iwasaki T, Togawa A, et al. (2000)
Hepatoma cell migration through a mesothelial cell monolayer is inhibited by
cyclic AMP-elevating agents via a Rho-dependent pathway. FEBS Lett 484:
69–73. S0014-5793(00)02129-3 [pii].
44. Kim A, Son M, Kim KI, Yang Y, Song EY, et al. (2009) Elevation of
intracellular cyclic AMP inhibits NF-kappaB-mediated thymosin beta4 expres-
sion in melanoma cells. Exp Cell Res 315: 3325–3335. S0014-4827(09)00243-2
[pii];10.1016/j.yexcr.2009.05.024 [doi].
45. Zhang A, Dong Z, Yang T (2006) Prostaglandin D2 inhibits TGF-beta1-induced
epithelial-to-mesenchymal transition in MDCK cells. Am J Physiol Renal
Physiol 291: F1332–F1342. 00131.2006 [pii];10.1152/ajprenal.00131.2006
[doi].
46. Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A, et al. (2009)
Expression and activity of phosphodiesterase isoforms during epithelial
mesenchymal transition: the role of phosphodiesterase 4. Mol Biol Cell 20:
4751–4765. E09-01-0019 [pii];10.1091/mbc.E09-01-0019 [doi].
47. Lyle KS, Raaijmakers JH, Bruinsma W, Bos JL, de RJ (2008) cAMP-induced
Epac-Rap activation inhibits epithelial cell migration by modulating focal
adhesion and leading edge dynamics. Cell Signal 20: 1104–1116. S0898-
6568(08)00037-5 [pii];10.1016/j.cellsig.2008.01.018 [doi].
48. Gilcrease MZ (2007) Integrin signaling in epithelial cells. Cancer Lett 247: 1–25.
S0304-3835(06)00211-4 [pii];10.1016/j.canlet.2006.03.031 [doi].
49. Pursiheimo JP, Kieksi A, Jalkanen M, Salmivirta M (2002) Protein kinase A
balances the growth factor-induced Ras/ERK signaling. FEBS Lett 521:
157–164. S0014579302028648 [pii].
50. Hayashi H, Sudo T (2009) Effects of the cAMP-elevating agents cilostamide,
cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in
platelets. Thromb Haemost 102: 327–335. TH08-12-0781 [pii];10.1160/TH08-
12-0781 [doi].
51. Iwasaki T, Chen JD, Kim JP, Wynn KC, Woodley DT (1994) Dibutyryl cyclic
AMP modulates keratinocyte migration without alteration of integrin expression.
J Invest Dermatol 102: 891–897.
VILIP-1 in Epithelial-Mesenchymal Transition
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33116